Daniela M. Dinulescu, Ph.D.

Publications

Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S.Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.Pr
20616005
Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q, Cheng KH, Urban N, Hanash SM, Dinulescu DM.Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer b
19936259
Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E.Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.Cancer Prev R
19737983
Abbott KL,Nairn AV,Hall EM,Horton MB,McDonald JF,Moremen KW,Dinulescu DM,Pierce M.Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.Proteomics. 2008 Aug;8(16):3210-20.
18690643
Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME.Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.Cell Cycle. 2007 Aug;6(21):2585-90.
17957144
Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T.A spatially and temporally restricted mouse model
17676052
Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Proc Natl Acad S
17088539
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance respo
16849428
Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK.Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.Cancer Res. 2006 Mar 1;66(5):2527-31.
16510568
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T.Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.Nat Med. 2005 Jan;11(1):63-70.
15619626
Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ.c-CBL is not required for leukemia induction by Bcr-Abl in mice.Oncogene. 2003 Dec 4;22(55):8852-60.
14654781

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Daniela M. Dinulescu, Ph.D. Publications Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S.Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.Pr 20616005 Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q, Cheng KH, Urban N, Hanash SM, Dinulescu DM.Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer b 19936259 Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E.Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.Cancer Prev R 19737983 Abbott KL,Nairn AV,Hall EM,Horton MB,McDonald JF,Moremen KW,Dinulescu DM,Pierce M.Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.Proteomics. 2008 Aug;8(16):3210-20. 18690643 Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME.Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.Cell Cycle. 2007 Aug;6(21):2585-90. 17957144 Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T.A spatially and temporally restricted mouse model 17676052 Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Proc Natl Acad S 17088539 Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance respo 16849428 Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK.Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.Cancer Res. 2006 Mar 1;66(5):2527-31. 16510568 Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T.Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.Nat Med. 2005 Jan;11(1):63-70. 15619626 Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ.c-CBL is not required for leukemia induction by Bcr-Abl in mice.Oncogene. 2003 Dec 4;22(55):8852-60. 14654781
Site Map Site Feedback Web Privacy Policy